FTC insists generics ANI and Novitium divest IP before merger

The Federal Trade Commission (FTC) has stipulated that generic drug marketers ANI Pharmaceuticals, and Novitium Pharma must divest IP rights to Prasco ahead of their $210 million merger.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotech

Regeneron and Amgen call a truce on two Eylea biosimilar patents

28 October 2026 Both companies have agreed to dismiss claims and counterclaims involving Amgen’s 2 mg aflibercept biosimilar, while their wider feud continues.

MedTech

HeartFlow targets AI cardiac imaging rival over patents and trade secrets

27 October 2026 The 179-page lawsuit alleges that a Boston-based company used patented technology and confidential information from former employees to develop a competing cardiac imaging product.

Careers

Womble Bond Dickinson loses trio of partners to US rival

27 October 2026 The departing partners bring expertise across molecular biology, biochemistry, small molecule and peptide drugs, including blockbuster therapies, as well as chemical and mechanical technologies.

More features

Regeneron and Amgen call a truce on two Eylea biosimilar patents

HeartFlow targets AI cardiac imaging rival over patents and trade secrets

Womble Bond Dickinson loses trio of partners to US rival

‘Companies that don’t leverage AI will struggle to keep up’: Umicore IP chief

Mewburn Ellis hires first CTO to boost investment in AI and digital innovation

10x and Parse set to end sequencing feud after appeals court defeat

Dr Reddy’s eyes appeal stakes as Boehringer hearing ends

Amarin and Hikma call time on six-year skinny label fight

FTC insists generics ANI and Novitium divest IP before merger

More on this story

Editor's picks

Editor's picks

More features